Geneva, Switzerland and Irvine, California – 08 September 2014 — Harbor MedTech Inc. and Sepropharm Export SARL today announced that they have signed a Distribution Agreement for Harbor MedTech’s Architect Fx and Architect Px advanced wound dressings. Sepropharm will distribute the products in the EU and Switzerland, plus certain other countries. In addition to the Distribution Agreement, Sepropharm will make an equity investment in Harbor MedTech. Details of the terms were not announced.

“We are extremely pleased to find a partner like Sepropharm for our product in Europe. We believe that we will be able to build upon this foundational agreement to create a mutually beneficial partnership between the companies for years to come.” said Jerry Mezger, CEO of Harbor MedTech.

“This is the first of several transactions as we build our wound care franchise in Europe.” stated Laurent Massuyeau, Principal Owner and President of Sepropharm. “To have access to unique products such as the Architect family of products provides Sepropharm with a very solid foundation from which to grow this aspect of our business”

Harbor MedTech was advised by the Kirchner Group, a traditional merchant bank, who introduced the parties and helped facilitate the distribution agreement. “We are always pleased when we find a fit from both from a business term and culture perspective” added Paul Kirkconnell, Managing Director of the Kirchner Group. “We believe this is the foundation in for a long term, international partnership. Both companies are driven by a very entrepreneurial spirit which is fundamental to their synergistic fit.”

About Harbor MedTech, Inc.
Harbor MedTech, Inc. is a diversified and fully integrated biologics tissue regeneration company. Harbor’s first product, Architect(r), is an extracellular collagen matrix used as a skin substitute for treating diabetic foot ulcers, venous leg ulcers, serious burns, and many other chronic skin wounds. Clinical studies have shown that Architect offers “best-in-class” wound healing at a much lower cost than the leading skin substitutes in use today. Architect is FDA cleared for use in the U.S. and Harbor anticipates getting regulatory approval for Europe by the end of 2014.

Jerry Mezger
President & CEO
Tel. 949.679.4800
jerrym@harbormedtech.com

About Sepropharm International
Founded in 1979, Sepropharm International is a privately held group of companies operating in the two areas of expertise; building, operating (and possibly transferring) dedicated pharmaceutical sales operations in Europe for biotechnology or pharmaceutical clients in Europe (mainly France, Germany, Italy, Spain) and distributing pharmaceutical clients in emerging markets, mainly French speaking Africa and Central Asia. Sepropharm, headquartered in Geneva, Switzerland employs 120 employees throughout the world and has offices in France, Germany, Switzerland and several emerging market regions. Sepropharm represents over 20 principals and generated market sales of 150 MUSD in 2012. Sepropharm collaborates with 6 of the top 15 worldwide pharmaceutical groups.

Laurent Massuyeau
President
Tel : +41225102932
Email: laurent.massuyeau@sepropharm.fr
Cc: estelle.journe@sepropharm.fr

About Kirchner Group
The Kirchner Group has provided traditional merchant banking services since 1985. The Company provides advisory, operational and transactional support to companies as well as asset management services for institutional investors. Kirchner Group’s proprietary platform is built on the premise that pairing deep domain expertise with process experts provides superior results. Our clients and partners range from promising entrepreneurs to Fortune 500 companies and their investors. Kirchner Group also manages assets for some of the largest insurance companies, commercial banks and institutional investors in the world.

Don Haliburton
Chief Operating Officer
+1 (205) 313-0784 x205
dhaliburton@kirchnergroup.com